Evidence map›Paper›PMID 40640096›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2025

[Advances in the Treatment of Multiple Primary Lung Cancer].

Ying Xiao, Xiaobo Chen, Xinghe Tong, Xudong Yang, Yanlong Yang, Yunping Zhao

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying XiaoDepartment of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650100, China.
Xiaobo ChenDepartment of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650100, China.
Xinghe TongDepartment of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650100, China.
Xudong YangDepartment of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650100, China.
Yanlong YangDepartment of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650100, China.
Yunping ZhaoDepartment of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650100, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the incidence of multiple primary lung cancer (MPLC) has been increasing, and it cannot be ignored in clinical practice. The treatment of MPLC is still controversial, but surgical treatment is recognized as the most important treatment. However, current studies have shown that the treatment of MPLC needs to develop multimodal treatment according to different patients. This review summarizes multiple treatment method for MPLC, including surgery, ablation, chemotherapy, radiotherapy, targeted therapy, and immunotherapy in order to enhance understanding of MPLC treatment.
.

Indexed as

Lung NeoplasmsCombined Modality TherapyHumansImmunotherapyAblationDrug therapyLung neoplasmsMultimodal therapyRadiation therapySurgery

Identifiers

PMID40640096
PMCPMC12257160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.